ScienceDex / Researcher record
Elke Lipka
- Tsrl, Inc. (no department on record)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $3,288,825 | 4 | #2,238 |
| 2025 | $3,097,238 | 3 | #3,232 |
| 2026 | $2,096,796 | 2 | #9,956 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20244 records
- FY20253 records
- FY2026 · selected2 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 10134933Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award records by amount
NIH award records listing Elke Lipka as a PI. Multi-PI records show the full award amount for context.
- 5R44DK143799-03R44Contact PIMicroneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease$1.1Maward amount
- 4U44AI184201-02U44Contact PIPhase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy Subjects$999.3Kaward amount
Award organization
Organizations that administered FY2026 awards listing Elke Lipka as a PI.
FY2026 award administered by Tsrl, Inc. (MI).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardTsrl, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #2238
- 2024Entered Top 25% NationallyRanked #2238
- 2025$5M Cumulative Funding